Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 3, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific equity transactions and does not contain financial performance data.
Material Changes
On March 2, 2005, the GlaxoSmithKline Employee Trust ("the GSK Trust") transferred 26,940 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on March 3, 2005.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—are noted as having an interest in the shares held within the GSK Trust in the same capacity as other employees. The filing contains no specific guidance, outlook, or discussion of risks beyond the disclosure of these share movements.
Investor Verification Points
- Verify the total number of shares transferred from the GSK Trust (26,940) and the date of transfer (March 2, 2005).
- Confirm the specific directors with interests in the GSK Trust: Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe.
- Note that this filing does not contain financial results; refer to the company's Form 20-F for comprehensive financial data.